Intra-Cellular Therapies, a prominent biopharmaceutical firm in the United States, is dedicated to discovering, clinically developing, and commercializing small molecule drugs that address medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS). The company's flagship product, CAPLYTA, has been developed for the treatment of schizophrenia and bipolar depression in adults. In addition, Intra-Cellular Therapies is at the forefront of developing Lumateperone, currently undergoing Phase 3 clinical trials for the treatment of various depressive disorders and other neuropsychiatric indications. The firm is also engaged in intensive research and development of Lenrispodun (ITI-214) for addressing Parkinson's disease, heart failure, CNS, along with other ailments, ITI-1284 for alleviating neuropsychiatric disorders and behavioral disturbances in dementia, and ITI-333 for dealing with substance use disorders, pain, and psychiatric comorbidities such as anxiety, depression, and sleep disorders. Established in 2002 and headquartered in New York, Intra-Cellular Therapies has consistently demonstrated its commitment to providing productive therapies for neuropsychiatric and neurological patients.
Intra-Cellular Therapies's ticker is ITCI
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 51-200 employees working at Intra-Cellular Therapies
It is intracellulartherapies.com
Intra-Cellular Therapies is in the Healthcare sector
Intra-Cellular Therapies is in the Biotechnology industry
The following five companies are Intra-Cellular Therapies's industry peers: